LR LossReserves.com
Back to The Wire Workers Comp

Florida Court Blocks Physician Drug Dispensing in WC Claims

The First DCA ruled that physicians are not pharmacists under Florida's workers' comp statute, ending reimbursement for physician-dispensed medications and removing a 171% pharmacy markup that inflated medical severity for self-insured employers.

Florida’s First District Court of Appeal ruled on February 25 that physicians cannot be reimbursed for dispensing medications directly to injured workers under the state’s workers’ compensation statute. The decision in Publix Super Markets, Inc. v. Department of Financial Services (Case No. 1D2023-0941) struck down a 2023 Division of Workers’ Compensation regulation that had reversed years of prior practice restricting physician dispensing. The Florida Legislature wrapped its 2026 session on March 13 without passing any override, confirming the ruling stands.

Who It Affects

Self-insured employers in Florida carrying workers’ comp retentions, along with their TPAs and fronting carriers. The ruling is most consequential for programs with high concentrations of treating physicians who dispensed at the point of care, particularly in orthopedic, pain management, and occupational medicine settings. Captives and group self-insurance funds covering Florida WC exposure should also recalibrate their pharmacy cost assumptions.

What the Court Said

The 1st DCA held that the “absolute choice” provision in Section 440.13(3)(j), which guarantees injured workers the right to choose their own pharmacy or pharmacist, does not extend to dispensing practitioners. Physicians, physician assistants, and advanced practice nurses registered to dispense under Section 465.0276 are not pharmacists within the meaning of the statute. That distinction means carriers and self-insured employers can deny authorization or reimbursement for physician-dispensed medications without violating the injured worker’s statutory choice rights.

The court set aside a Division of Administrative Hearings order that had upheld the 2023 DWC regulation. Publix, joined by Normandy Insurance, Zenith Insurance, Bridgefield Employers Insurance, and others, had challenged the rule. The Florida Insurance Council and the American Property Casualty Insurance Association (APCIA) filed amicus briefs supporting the challenge.

The Reserve Mechanism: Pharmacy Severity Drops

The cost gap between physician-dispensed and retail pharmacy medications has been well documented. Workers’ Compensation Research Institute data cited in the proceedings showed Vicodin at $1.41 per pill when dispensed by a physician versus $0.52 at a retail pharmacy, a 171% markup. Mobic ran $5.86 per pill from a physician versus $3.19 at a pharmacy. The Florida Insurance Council and APCIA estimated that eliminating physician dispensing would save Florida WC payers approximately $43 million over five years.

For self-insured employers, the savings flow directly into the medical severity component of the loss triangle. Pharmacy costs are embedded in the medical payment column. When a structural markup disappears by operation of law, the expected cost per claim drops on every open claim and every unreported claim in the IBNR estimate. Programs that previously saw a 15% to 20% premium over retail pharmacy benchmarks on physician-dispensed claims should expect that gap to close in Q1 and Q2 2026 data.

This is the type of identifiable severity shift that shows up in the diagnostic framework for understanding what drives IBNR higher, except here the direction is favorable. The pharmacy cost component is a measurable line item, and the change has a clean effective date.

What This Means for Your Next Review

Ask your actuary whether the Florida WC medical severity assumption has been adjusted to reflect the dispensing prohibition as of February 2026. If your TPA can isolate pharmacy costs in the Florida triangle, compare Q1 and Q2 2026 against prior periods to measure the actual savings. Watch whether NCCI incorporates the dispensing change into its next Florida loss cost filing, which would confirm the severity reduction at the system level. If the pharmacy industry appeals to the Florida Supreme Court, monitor that timeline, but do not delay the adjustment. The ruling is effective now, and the data should already reflect it.

Sources